menu
Home   |   Drugs   |   Ingredients   |   Pharma Companies   |   ATC   |   ICD
Share on Facebook Tweet

Rasilez

How often in a day do you take medicine? How many times?

Rasilez uses



Contraindications (4) 3/2015

Warnings and Precautions (5.2, 5.5) 3/2015

WARNING: FETAL TOXICITY


WARNING: FETAL TOXICITY

See full prescribing information for complete boxed warning.

1 INDICATIONS AND USAGE

Rasilez is a renin inhibitor indicated for:


Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

1.1 Hypertension

Rasilez is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating risk reduction with Rasilez.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality have also been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

2 DOSAGE AND ADMINISTRATION

2.1 Hypertension

The usual recommended starting dose of Rasilez is 150 mg once daily. In patients whose blood pressure is not adequately controlled, the daily dose may be increased to 300 mg. Doses above 300 mg did not give an increased blood pressure response but resulted in an increased rate of diarrhea. The antihypertensive effect of a given dose is substantially attained (85% to 90%) by 2 weeks.

2.2 Relationship to Meals

Patients should establish a routine pattern for taking Rasilez with regard to meals. High fat meals decrease absorption substantially .

3 DOSAGE FORMS AND STRENGTHS

150 mg light pink biconvex round tablet, imprinted NVR/IL (Side 1/Side 2)

300 mg light red biconvex ovaloid round tablet, imprinted NVR/IU (Side 1/Side 2)

Tablets: 150 mg, 300 mg (3)

4 CONTRAINDICATIONS

Do not use Rasilez with ARBs or ACEIs in patients with diabetes .

Rasilez is contraindicated in patients with known hypersensitivity to any of the components .

Do not use with angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) in patients with diabetes. (4)

Hypersensitivity to any of the components. (4)

5 WARNINGS AND PRECAUTIONS

5.1 Fetal Toxicity

Pregnancy Category D

Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Rasilez as soon as possible .

5.2 Renal Impairment/Hyperkalemia/Hypotension when Rasilez is Given in Combination with ARBs or ACEIs

Rasilez is contraindicated in patients with diabetes who are receiving ARBs or ACEIs because of the increased risk of renal impairment, hyperkalemia, and hypotension. In general, avoid combined use of Rasilez with ACE inhibitors or ARBs, particularly in patients with creatinine clearance less than 60 mL/min .

5.3 Anaphylactic Reactions and Head and Neck Angioedema

Hypersensitivity reactions such as anaphylactic reactions and angioedema of the face, extremities, lips, tongue, glottis and/or larynx have been reported in patients treated with Rasilez and has necessitated hospitalization and intubation. This may occur at any time during treatment and has occurred in patients with and without a history of angioedema with ACEIs or angiotensin receptor antagonists. Anaphylactic reactions have been reported from postmarketing experience with unknown frequency. If angioedema involves the throat, tongue, glottis or larynx, or if the patient has a history of upper respiratory surgery, airway obstruction may occur and be fatal. Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. Prompt administration of subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and measures to ensure a patent airway may be necessary.

Discontinue Rasilez immediately in patients who develop anaphylactic reactions or angioedema, and do not readminister .

5.4 Hypotension

Symptomatic hypotension may occur after initiation of treatment with Rasilez in patients with marked volume depletion, patients with salt depletion, or with combined use of Rasilez and other agents acting on the renin-angiotensin-aldosterone system. The volume or salt depletion should be corrected prior to administration of Rasilez, or the treatment should start under close medical supervision.

A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized.

5.5 Impaired Renal Function

Monitor renal function periodically in patients treated with Rasilez. Changes in renal function, including acute renal failure, can be caused by drugs that affect the RAAS. Patients whose renal function may depend in part on the activity of the RAAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or patients receiving ARB, ACEI or nonsteroidal anti-inflammatory drug (NSAID), including selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors), therapy may be at particular risk for developing acute renal failure on Rasilez . Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function.

5.6 Hyperkalemia

Monitor serum potassium periodically in patients receiving Rasilez. Drugs that affect the RAAS can cause hyperkalemia. Risk factors for the development of hyperkalemia include renal insufficiency, diabetes, combination use with ARBs or ACEIs , NSAIDs, or potassium supplements or potassium sparing diuretics.

5.7 Cyclosporine or Itraconazole

When Rasilez was given with cyclosporine or itraconazole, the blood concentrations of Rasilez were significantly increased. Avoid concomitant use of Rasilez with cyclosporine or itraconazole .

6 ADVERSE REACTIONS

Most common adverse reaction: diarrhea (6.1)


To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Clinical Trials Experience

The following serious adverse reactions are discussed in greater detail in other sections of the label:


Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.

Data described below reflect the evaluation of the safety of Rasilez in more than 6,460 patients, including over 1,740 treated for longer than 6 months, and more than 1,250 patients for longer than 1 year. In placebo controlled clinical trials, discontinuation of therapy due to a clinical adverse event, including uncontrolled hypertension, occurred in 2.2% of patients treated with Rasilez versus 3.5% of patients given placebo. These data do not include information from the ALTITUDE study which evaluated the use of Rasilez in combination with ARBs or ACEIs .

Angioedema: Two cases of angioedema with respiratory symptoms were reported with Rasilez use in the clinical studies. Two other cases of periorbital edema without respiratory symptoms were reported as possible angioedema and resulted in discontinuation. The rate of these angioedema cases in the completed studies was 0.06%.

In addition, 26 other cases of edema involving the face, hands, or whole body were reported with Rasilez use including 4 leading to discontinuation.

In the placebo controlled studies, however, the incidence of edema involving the face, hands, or whole body was 0.4% with Rasilez compared with 0.5% with placebo. In a long-term active-control study with Rasilez and hydrochlorothiazide (HCTZ) arms, the incidence of edema involving the face, hand or whole body was 0.4% in both treatment arms .

Gastrointestinal: Tekturna produces dose-related gastrointestinal (GI) adverse reactions. Diarrhea was reported by 2.3% of patients at 300 mg, compared to 1.2% in placebo patients. In women and the elderly (age 65 years and older) increases in diarrhea rates were evident starting at a dose of 150 mg daily, with rates for these subgroups at 150 mg comparable to those seen at 300 mg for men or younger patients (all rates about 2.0% to 2.3%). Other GI symptoms included abdominal pain, dyspepsia, and gastroesophageal reflux, although increased rates for abdominal pain and dyspepsia were distinguished from placebo only at 600 mg daily. Diarrhea and other GI symptoms were typically mild and rarely led to discontinuation.

Cough: Rasilez was associated with a slight increase in cough in the placebo-controlled studies (1.1% for any Rasilez use versus 0.6% for placebo). In active-controlled trials with ACE inhibitor (ramipril, lisinopril) arms, the rates of cough for the Rasilez arms were about one-third to one-half the rates in the ACE inhibitor arms.

Seizures: Single episodes of tonic-clonic seizures with loss of consciousness were reported in 2 patients treated with Rasilez in the clinical trials. One of these patients did have predisposing causes for seizures and had a negative electroencephalogram (EEG) and cerebral imaging following the seizures (for the other patient EEG and imaging results were not reported). Rasilez was discontinued and there was no rechallenge.

Other adverse effects with increased rates for Rasilez compared to placebo included rash (1% versus 0.3%), elevated uric acid (0.4% versus 0.1%), gout (0.2% versus 0.1%) and renal stones (0.2% versus 0%).

Aliskiren’s effect on ECG intervals was studied in a randomized, double-blind, placebo and active-controlled (moxifloxacin), 7-day repeat dosing study with Holter-monitoring and 12 lead ECGs throughout the interdosing interval. No effect of Rasilez on QT interval was seen.

Clinical Laboratory Findings

In controlled clinical trials, clinically relevant changes in standard laboratory parameters were rarely associated with the administration of Rasilez in patients with hypertension not concomitantly treated with an ARB or ACEI. In multiple-dose studies in hypertensive patients, Rasilez had no clinically important effects on total cholesterol, HDL, fasting triglycerides, or fasting glucose.

Blood Urea Nitrogen, Creatinine: In patients with hypertension not concomitantly treated with an ARB or ACEI, minor increases in blood urea nitrogen (BUN) or serum creatinine were observed in less than 7% of patients treated with Rasilez alone versus 6% on placebo .

Hemoglobin and Hematocrit: Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.08 g/dL and 0.16 volume percent, respectively, for all Rasilez monotherapy) were observed. The decreases were dose-related and were 0.24 g/dL and 0.79 volume percent for 600 mg daily. This effect is also seen with other agents acting on the renin angiotensin system, such as angiotensin inhibitors and ARBs and may be mediated by reduction of angiotensin II which stimulates erythropoietin production via the AT1 receptor. These decreases led to slight increases in rates of anemia with Rasilez compared to placebo were observed (0.1% for any Rasilez use, 0.3% for Rasilez 600 mg daily, versus 0% for placebo). No patients discontinued therapy due to anemia.

Serum Potassium: In patients with hypertension not concomitantly treated with an ARB or ACEI, increases in serum potassium greater than 5.5 mEq/L were infrequent (0.9% compared to 0.6% with placebo) .

Serum Uric Acid: Rasilez monotherapy produced small median increases in serum uric acid levels (about 6 micromol/L) while HCTZ produced larger increases (about 30 micromol/L). The combination of Rasilez with HCTZ appears to be additive (about 40 micromol/L increase). The increases in uric acid appear to lead to slight increases in uric acid-related AEs: elevated uric acid (0.4% versus 0.1%), gout (0.2% versus. 0.1%), and renal stones (0.2% versus 0%).

Creatine Kinase: Increases in creatine kinase of greater than 300% were recorded in about 1% of Rasilez monotherapy patients versus 0.5% of placebo patients. Five cases of creatine kinase rises, 3 leading to discontinuation and 1 diagnosed as subclinical rhabdomyolysis, and another as myositis, were reported as adverse events with Rasilez use in the clinical trials. No cases were associated with renal dysfunction.

6.2 Postmarketing Experience

The following adverse reactions have been reported in Rasilez postmarketing experience. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or establish a causal relationship to drug exposure.

Hypersensitivity: anaphylactic reactions and angioedema requiring airway management and hospitalization

Urticaria

Peripheral edema

Hepatic enzyme increase with clinical symptoms of hepatic dysfunction

Severe cutaneous adverse reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis

Pruritus

Erythema

Nausea Vomiting

7 DRUG INTERACTIONS

Cyclosporine: Avoid coadministration of cyclosporine with Rasilez .

Itraconazole: Avoid coadministration of itraconazole with Rasilez .

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) including selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors with agents that affect the RAAS, including Rasilez, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Rasilez and NSAID therapy.

The antihypertensive effect of Rasilez may be attenuated by NSAIDs.

Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAAS): The concomitant use of Rasilez with other agents acting on the RAAS such as ACEIs or ARBs is associated with an increased risk of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two drugs that inhibit the renin-angiotensin system do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of Rasilez with ACE inhibitors or ARBs, particularly in patients with CrCl less than 60 mL/min. Monitor blood pressure, renal function, and electrolytes in patients taking Rasilez and other agents that affect the RAAS .

The concomitant use of Rasilez with an ARB or an ACEI in diabetic patients is contraindicated .

Furosemide: Oral coadministration of Rasilez and furosemide reduced exposure to furosemide. Monitor diuretic effects when furosemide is coadministered with Rasilez.

8 USE IN SPECIFIC POPULATIONS

Nursing Mothers: Adverse reactions may occur in nursing infants.

8.1 Pregnancy

Pregnancy Category D

Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Rasilez as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimesters of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus.

In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue Rasilez, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to Rasilez for hypotension, oliguria, and hyperkalemia .

8.3 Nursing Mothers

It is not known whether Rasilez is excreted in human breast milk. Rasilez was secreted in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

8.4 Pediatric Use

Safety and effectiveness of Rasilez in pediatric patients younger than 18 years have not been established.

Preclinical studies indicate a potential for substantial increase in exposure to Rasilez in pediatric patients .

Neonates with a history of in utero exposure to Rasilez

If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function.

8.5 Geriatric Use

Of the total number of patients receiving Rasilez in clinical studies, 1,275 (19%) were 65 years or older and 231 (3.4%) were 75 years or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

8.6 Renal Impairment

Safety and effectiveness of Rasilez in patients with severe renal impairment [creatinine clearance (CrCl) less than 30 mL/min] have not been established as these patients were excluded in clinical trials .

10 OVERDOSAGE

Limited data are available related to overdosage in humans. The most likely manifestation of overdosage would be hypotension. If symptomatic hypotension occurs, supportive treatment should be initiated.

Rasilez is poorly dialyzed. Therefore, hemodialysis is not adequate to treat Rasilez overexposure .

11 DESCRIPTION

Rasilez contains Rasilez hemifumarate, direct renin inhibitor, that is provided as tablets for oral administration. Rasilez hemifumarate is chemically described as (2S,4S,5S,7S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide hemifumarate and its structural formula is:

*Ketoconazole: A 400 mg once daily dose was not studied, but would be expected to increase Rasilez blood levels further.

**Ramipril, valsartan, irbesartan: In general, avoid combined use of Rasilez with ACE inhibitors or ARBs, particularly in patients with CrCl less than 60 mL/min .

Warfarin: There was no clinically significant effect of a single dose of warfarin 25 mg on the pharmacokinetics of Rasilez.

*Furosemide: Patients receiving furosemide could find its effects diminished after starting Rasilez. In patients with heart failure, coadministration of Rasilez (300 mg/day) reduced plasma AUC and Cmax of oral furosemide (60 mg/day) by 17% and 27%, respectively, and reduced 24 hour urinary furosemide excretion by 29%. This change in exposure did not result in statistically significant difference in total urine volume and urinary sodium excretion over 24 hours. However, a transient decrease in urinary sodium excretion and urine volume effects up to 12 hours were observed when furosemide was coadministered with Rasilez 300 mg/day.

**Ramipril, valsartan: In general, avoid combined use of Rasilez with ACE inhibitors or ARBs, particularly in patients with CrCl less than 60 mL/min .

Special Populations

Renally Impaired Patients: Rasilez was evaluated in patients with varying degrees of renal insufficiency. The rate and extent of exposure (AUC and Cmax) of Rasilez in subjects with renal impairment did not show a consistent correlation with the severity of renal impairment. Adjustment of the starting dose is not required in these patients .

The pharmacokinetics of Rasilez following administration of a single oral dose of 300 mg was evaluated in patients with End Stage Renal Disease (ESRD) undergoing hemodialysis. When compared to matched healthy subjects, changes in the rate and extent of Rasilez exposure (Cmax and AUC) in ESRD patients undergoing hemodialysis were not clinically significant.

Timing of hemodialysis did not significantly alter the pharmacokinetics of Rasilez in ESRD patients. Therefore, no dose adjustment is warranted in ESRD patients receiving hemodialysis.

Hepatically Impaired Patients: The pharmacokinetics of Rasilez were not significantly affected in patients with mild to severe liver disease. Consequently, adjustment of the starting dose is not required in these patients.

Pediatric Patients: The pharmacokinetics of Rasilez have not been investigated in patients younger than 18 years of age.

Geriatric Patients: Exposure (measured by AUC) is increased in elderly patients 65 years and older. Adjustment of the starting dose is not required in these patients.

Race: The pharmacokinetic differences between blacks, Caucasians, and Japanese are minimal.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenic potential was assessed in a 2-year rat study and a 6-month transgenic mouse study with Rasilez hemifumarate at oral doses of up to 1500 mg aliskiren/kg/day. Although there were no statistically significant increases in tumor incidence associated with exposure to Rasilez, mucosal epithelial hyperplasia (with or without erosion/ulceration) was observed in the lower gastrointestinal tract at doses of greater than or equal to 750 mg/kg/day in both species, with a colonic adenoma identified in 1 rat and a cecal adenocarcinoma identified in another, rare tumors in the strain of rat studied. On a systemic exposure (AUC0-24hr) basis, 1500 mg/kg/day in the rat is about 4 times and in the mouse about 1.5 times the maximum recommended human dose (MRHD) (300 mg aliskiren/day). Mucosal hyperplasia in the cecum or colon of rats was also observed at doses of 250 mg/kg/day (the lowest tested dose) as well as at higher doses in 4- and 13-week studies.

Rasilez hemifumarate was devoid of genotoxic potential in the Ames reverse mutation assay with S. typhimurium and E. coli, the in vitro Chinese hamster ovary cell chromosomal aberration assay, the in vitro Chinese hamster V79 cell gene mutation test and the in vivo mouse bone marrow micronucleus assay.

Fertility of male and female rats was unaffected at doses of up to 250 mg aliskiren/kg/day (8 times the MRHD of 300 mg Tekturna/60 kg on a mg/m2 basis.)

13.2 Animal Toxicology and/or Pharmacology

Reproductive Toxicology Studies: Reproductive toxicity studies of Rasilez hemifumarate did not reveal any evidence of teratogenicity at oral doses up to 600 mg aliskiren/kg/day (20 times the MRHD of 300 mg/day on a mg/m2 basis) in pregnant rats or up to 100 mg aliskiren/kg/day (7 times the MRHD on a mg/m2 basis) in pregnant rabbits. Fetal birth weight was adversely affected in rabbits at 50 mg/kg/day (3.2 times the MRHD on a mg/m2 basis). Rasilez was present in placenta, amniotic fluid and fetuses of pregnant rabbits.

Juvenile Animal Studies

Juvenile toxicity studies indicated increased systemic exposure to Rasilez 85- to 385-fold in 14 day and 8 day old rats respectively, compared with adult rats. The mdr1 gene expression in juvenile rats was also significantly lower when compared to adult rats. The increased Rasilez exposure in juvenile rats appears to be mainly attributed to lack of maturation of P-gp. The overexposure in juvenile rats was associated with high mortality .

14 CLINICAL STUDIES

14.1 Aliskiren Monotherapy

The antihypertensive effects of Rasilez have been demonstrated in 6 randomized, double-blind, placebo-controlled 8-week clinical trials in patients with mild-to-moderate hypertension. The placebo response and placebo-subtracted changes from baseline in seated trough cuff blood pressure are shown in Table 1.

*p value less than 0.05 versus placebo by ANCOVA with Dunnett’s procedure for multiple comparisons
†p value less than 0.05 versus placebo by ANCOVA for the pairwise comparison.
Rasilez daily dose, mg
Study Placebo

mean change

 75 150 300 600
Placebo-subtracted Placebo-subtracted Placebo-subtracted Placebo-subtracted
1 2.9/3.3 5.7/4* 5.9/4.5* 11.2/7.5* --
2 5.3/6.3 -- 6.1/2.9* 10.5/5.4* 10.4/5.2*
3 10/8.6 2.2/1.7 2.1/1.7 5.1/3.7* --
4 7.5/6.9 1.9/1.8 4.8/2* 8.3/3.3* --
5 3.8/4.9 -- 9.3/5.4* 10.9/6.2* 12.1/7.6*
6 4.6/4.1 -- -- 8.4/4.9† --

The studies included approximately 2,730 patients given doses of 75 to 600 mg of Rasilez and 1,231 patients given placebo. As shown in Table 1, there is some increase in response with administered dose in all studies, with reasonable effects seen at 150mg to 300 mg, and no clear further increases at 600 mg. A substantial proportion of the blood pressure lowering effect was observed within 2 weeks of treatment. Studies with ambulatory blood pressure monitoring showed reasonable control throughout the interdosing interval; the ratios of mean daytime to mean nighttime ambulatory BP range from 0.6 to 0.9.

Patients in the placebo-controlled trials continued open-label Rasilez for up to 1 year. A persistent blood pressure lowering effect was demonstrated by a randomized withdrawal study (patients randomized to continue drug or placebo), which showed a statistically significant difference between patients kept on Rasilez and those randomized to placebo. With cessation of treatment, blood pressure gradually returned toward baseline levels over a period of several weeks. There was no evidence of rebound hypertension after abrupt cessation of therapy.

Rasilez lowered blood pressure in all demographic subgroups, although black patients tended to have smaller reduction than Caucasians and Asians, as has been seen with ACEIs and ARBs.

There are no studies of Rasilez or members of the direct renin inhibitors demonstrating reductions in cardiovascular risk in patients with hypertension.

14.2 Aliskiren in Combination with Other Antihypertensives

Hydrochlorothiazide (HCTZ)

Rasilez 75, 150, and 300 mg and HCTZ 6.25, 12.5, and 25 mg were studied alone and in combination in an 8-week, 2,776-patient, randomized, double-blind, placebo-controlled, parallel-group, 15-arm factorial study. Blood pressure reductions with the combinations were greater than the reductions with the monotherapies as shown in Table 2.

Hydrochlorothiazide, mg
Rasilez, mg Placebo mean change 0 6.25 12.5 25
Placebo-subtracted Placebo-subtracted Placebo-subtracted Placebo-subtracted
0 7.5/6.9 -- 3.5/2.1 6.4/3.2 6.8/2.4
75 -- 1.9/1.8 6.8/3.8 8.2/4.2 9.8/4.5
150 -- 4.8/2 7.8/3.4 10.1/5 12/5.7
300 -- 8.3/3.3 -- 12.3/7 13.7/7.3

Valsartan

Rasilez 150 mg and 300 mg and valsartan 160 mg and 320 mg were studied alone and in combination in an 8-week, 1,797-patient, randomized, double-blind, placebo-controlled, parallel-group, 4-arm, dose-escalation study. The dosages of Rasilez and valsartan were started at 150 mg and 160 mg, respectively, and increased at 4 weeks to 300 mg and 320 mg, respectively. Seated trough cuff blood pressure was measured at baseline, 4, and 8 weeks. Blood pressure reductions with the combinations were greater than the reductions with the monotherapies as shown in Table 3. In general, the combination of Rasilez and angiotensin receptor blocker should be avoided .

* The placebo change is 5.2/4.8 for week 4 endpoint which was used for the dose groups containing Rasilez 150 mg or Valsartan 160 mg.
Rasilez, mg Placebo mean change Valsartan, mg
0 160 320
0 4.6/4.1* -- 5.6/3.9 8.2/5.6
150 -- 5.4/2.7 10.0/5.7 --
300 -- 8.4/4.9 -- 12.6/8.1

Amlodipine

Rasilez 150 mg and 300 mg and amlodipine besylate 5 mg and 10 mg were studied alone and in combination in an 8-week, 1,685-patient, randomized, double-blind, placebo-controlled, multifactorial study. Treatment with Rasilez and amlodipine resulted overall in significantly greater reductions in diastolic and systolic blood pressure compared to the respective monotherapy components as shown in Table 4.

Rasilez, mg Placebo mean change Amlodipine, mg
0 5 10
0 5.4/6.8 -- 5.6/9.0 8.5/14.3
150 -- 2.6/3.9 8.6/13.9 10.8/17.1
300 -- 4.9/8.6 9.6/15.0 11.1/16.4

14.3 Aliskiren in Patients with Diabetes Treated with ARB or ACEI

Patients with diabetes with renal disease (defined either by the presence of albuminuria or reduced GFR) were randomized to Rasilez 300 mg daily (n=4296) or placebo (n=4310). All patients were receiving background therapy with an ARB or ACEI. The primary efficacy outcome was the time to the first event of the primary composite endpoint consisting of cardiovascular death, resuscitated sudden death, nonfatal myocardial infarction, nonfatal stroke, unplanned hospitalization for heart failure, onset of end stage renal disease, renal death, and doubling of serum creatinine concentration from baseline sustained for at least 1 month. After a median follow up of about 32 months, the trial was terminated early for lack of efficacy. Higher risk of renal impairment, hypotension and hyperkalemia was observed in Rasilez compared to placebo-treated patients, as shown in Table 5.

†renal failure, renal failure acute, renal failure chronic, renal impairment
††dizziness, dizziness postural, hypotension, orthostatic hypotension, presyncope, syncope
††† Given the variable baseline potassium levels of patients with renal insufficiency on dual RAAS therapy, the reporting of adverse event of hyperkalemia was at the discretion of the investigator.
* A Serious Adverse Event (SAE) is defined as: an event which is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization, or is medically significant (i.e., defined as an event that jeopardizes the patient or may require medical or surgical intervention to prevent one of the outcomes previously listed).
Rasilez

N=4272

 Placebo

N=4285
Serious Adverse Events* (%) Adverse Events (%) Serious Adverse Events* (%) Adverse Events (%)
Renal impairment † 5.7 14.5 4.3 12.4
Hypotension †† 2.3 19.9 1.9 16.3
Hyperkalemia ††† 1.0 38.9 0.5 28.8

The risk of stroke (3.4% Rasilez versus 2.7% placebo) and death (8.4% Rasilez versus 8.0% placebo) were also numerically higher in Rasilez treated patients.

16 HOW SUPPLIED/STORAGE AND HANDLING

Rasilez is supplied as a light-pink, biconvex round tablet containing 150 mg of Rasilez, and as a light-red biconvex ovaloid tablet containing 300 mg of Rasilez. Tablets are imprinted with NVR on one side and IL, IU, on the other side of the 150 mg and 300 mg tablets, respectively.

All strengths are packaged in bottles and unit-dose blister packages (10 strips of 10 tablets) as described below in Table 6.

Tablet Color Imprint Imprint NDC 0078-XXXX-XX
Side 1 Side 2 Bottle of 30 Bottle of 90 Blister Packages of 100
150 mg Light-Pink NVR IL 0485-15 0485-34 0485-35
300 mg Light-Red NVR IU 0486-15 0486-34 0486-35

Store at 25ºC (77ºF); excursions permitted to 15ºC to 30ºC (59 ºF to 86ºF). Protect from moisture.

Dispense in original container.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information)

Information for Patients

Pregnancy: Advise female patients of child bearing age about the consequences of exposure to Rasilez during pregnancy. Discuss treatment options with women planning to become pregnant. Advise patients to report pregnancies to their physicians as soon as possible.

Anaphylactic Reactions and Angioedema: Advise patients to immediately report any signs or symptoms suggesting a severe allergic reaction (difficulty breathing or swallowing, tightness of the chest, hives, general rash, swelling, itching, dizziness, vomiting, or abdominal pain) or angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physicians. Angioedema, including laryngeal edema, may occur at any time during treatment with Rasilez.

Symptomatic Hypotension: Advise patients that lightheadedness can occur, especially during the first days of Rasilez therapy, and that it should be reported to the prescribing physician. Advise patients that if syncope occurs, Rasilez should be discontinued until the physician has been consulted.

Caution patients that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope.

Potassium Supplements: Advise patients receiving Rasilez not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician.

Relationship to Meals: Advise patients to establish a routine pattern for taking Rasilez with regard to meals. High-fat meals decrease absorption substantially.

T2015-161

December 2015

PATIENT INFORMATION

Rasilez® (tek-turn-a)

(aliskiren)

Tablets

Read the Patient Information that comes with Rasilez before you start taking it and each time you get a refill. There may be new information. This leaflet does not replace talking to your doctor about your condition or treatment. If you have any questions about Rasilez, ask your doctor or pharmacist.

What is the most important information I should know about Rasilez?

Rasilez can cause harm or death to an unborn baby. Talk to your doctor about other ways to lower your blood pressure if you plan to become pregnant. If you get pregnant while taking Rasilez, tell your doctor right away.

What Is Rasilez?

Rasilez can help your blood vessels relax and widen so blood pressure is lower. Rasilez is a type of prescription medicine called a direct renin inhibitor (DRI). By reducing renin, it helps to reduce blood pressure.

What Is High Blood Pressure (Hypertension)?

Blood pressure is the force that pushes the blood through your blood vessels to all the organs of your body. You have high blood pressure when the force of your blood moving through your blood vessels is too great. Renin (pronounced REE-nin) is a chemical in the body that starts a process that makes blood vessels narrow, leading to high blood pressure. Drugs that lower blood pressure lower your risk of having a stroke or heart attack.

High blood pressure makes the heart work harder to pump blood throughout the body and causes damage to the blood vessels. If high blood pressure is not treated, it can lead to stroke, heart attack, heart failure, kidney failure, and vision problems.

Who Should Not Take Rasilez?

Do not take Rasilez if:


What Should I Tell My Doctor Before Taking Rasilez?

Tell your doctor about all your medical conditions, including whether you:


Tell your doctor about all the medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements.

Especially tell your doctor if you are taking:


Ask your doctor if you are not sure whether you are taking one of the medicines listed above. Know the medicines you take. Keep a list of them to show your doctor or pharmacist when you get a new medicine. Your doctor or pharmacist will know what medicines are safe to take together.

How Should I Take Rasilez?


What Are Possible Side Effects Of Rasilez?

Rasilez may cause serious side effects:


Common side effects of Rasilez include:

diarrhea

cough

dizziness

headache

flu-like symptoms

tiredness

high levels of potassium in the blood (hyperkalemia)

Less common side effects include rash, severe skin reactions (signs may include severe blistering of the lips, eyes or mouth, rash with fever and skin peeling) and liver disorder (signs may include nausea, loss of appetite, dark colored urine or yellowing of skin and eyes).

Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of Rasilez. For a complete list of side effects, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How Do I Store Rasilez?


General Information About Rasilez

Medicines are sometimes prescribed for conditions not listed in the patient information leaflet. Do not take Rasilez for a condition for which it was not prescribed. Do not give Rasilez to other people, even if they have the same condition or symptoms you have. It may harm them.

This leaflet summarizes the most important information about Rasilez. If you have more questions about Rasilez talk with your doctor or pharmacist. You can ask your doctor or pharmacist for information that is written for healthcare professionals.

For more information about Rasilez, ask your doctor or pharmacist, visit www. Tekturna.com , or call 1-888-Tekturna (1-888-835-8876).

What are the ingredients in Rasilez?

Active Ingredients: Rasilez hemifumarate

Inactive Ingredients: colloidal silicone dioxide, crospovidone, hypromellose, iron oxide colorants, magnesium stearate, microcrystalline cellulose, polyethylene glycol, talc, and titanium dioxide.

Distributed by:

Novartis Pharmaceuticals Corporation

East Hanover, NJ 07936

© Novartis

T2015-162

December 2015

Rasilez pharmaceutical active ingredients containing related brand and generic drugs:


Rasilez available forms, composition, doses:


Rasilez destination | category:


Rasilez Anatomical Therapeutic Chemical codes:


Rasilez pharmaceutical companies:


References

  1. Dailymed."ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
  2. "Aliskiren". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).
  3. "Aliskiren". http://www.drugbank.ca/drugs/DB0902... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Rasilez?

Depending on the reaction of the Rasilez after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Rasilez not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Rasilez addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

advertisement

Review

sdrugs.com conducted a study on Rasilez, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Rasilez consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

Visitor reported useful

No survey data has been collected yet

Visitor reported side effects

No survey data has been collected yet

Visitor reported price estimates

No survey data has been collected yet

Visitor reported frequency of use

No survey data has been collected yet

Visitor reported doses

No survey data has been collected yet

Visitor reported time for results

No survey data has been collected yet

Visitor reported administration

No survey data has been collected yet

Visitor reported age

No survey data has been collected yet

Visitor reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 22 here

The information was verified by Dr. Rachana Salvi, MD Pharmacology


| About | Privacy Policy
© 2002 - 2024 "sdrugs.com". All Rights Reserved